VIVUS Inc (VVUS.OQ)

VVUS.OQ on NASDAQ Stock Exchange Global Select Market

14.99USD
1 Aug 2013
Price Change (% chg)

$0.18 (+1.22%)
Prev Close
$14.81
Open
$14.92
Day's High
$15.07
Day's Low
$14.89
Volume
562,818
Avg. Vol
604,951
52-wk High
$24.86
52-wk Low
$9.86

VVUS.OQ

Chart for VVUS.OQ

About

VIVUS, Inc. is a biopharmaceutical company. It commercializes and develops therapies to address unmet needs in obesity, sleep apnea, diabetes and sexual health. Its drug, Qsymia (phentermine and topiramate extended-release) was approved by the the United States Food and Drug Administration (FDA) for the treatment of obesity as... (more)

Overall

Beta: 1.31
Market Cap (Mil.): $1,493.81
Shares Outstanding (Mil.): 100.80
Dividend: --
Yield (%): --

Financials

  VVUS.OQ Industry Sector
P/E (TTM): -- 37.93 37.76
EPS (TTM): -1.74 -- --
ROI: -69.73 19.48 18.76
ROE: -69.73 20.17 19.59
Search Stocks

First Manhattan's point man on Vivus: Doctor and Buffett disciple

NEW YORK - When Dr. Sam Colin was an intern at the Yale School of Medicine, he often gave up the chance to catch a few minutes of sleep between shifts to read the latest investment insights from Warren Buffett.

19 Jul 2013

First Manhattan's point man on Vivus: Doctor and Buffett disciple

NEW YORK, July 19 - When Dr. Sam Colin was an intern at the Yale School of Medicine, he often gave up the chance to catch a few minutes of sleep between shifts to read the latest investment insights from Warren Buffett.

19 Jul 2013

Market Chatter-Corporate finance press digest

July 19 - The following corporate finance-related stories were reported by media on Friday:

19 Jul 2013

Vivus set to give First Manhattan board majority -source

NEW YORK - Obesity drugmaker Vivus Inc is close to reaching a settlement with First Manhattan Co, giving the dissident investor a majority of the company board, a source familiar with the matter told Reuters on Thursday evening.

19 Jul 2013

UPDATE 3-Vivus gives First Manhattan board majority, Zook to be CEO

* First Manhattan was pushing to replace entire Vivus board

19 Jul 2013

Vivus vote delayed as company talks with shareholder-sources

NEW YORK - Obesity drugmaker Vivus Inc has delayed its board election, which was scheduled for Thursday morning, as it negotiates with shareholder First Manhattan Co, according to two sources familiar with the situation.

18 Jul 2013

UPDATE 1-Vivus vote delayed as company talks with shareholder-sources

NEW YORK, July 18 - Obesity drugmaker Vivus Inc has delayed its board election, which was scheduled for Thursday morning, as it negotiates with shareholder First Manhattan Co, according to two sources familiar with the situation.

18 Jul 2013

Vivus vote delayed as company negotiates with First Manhattan-sources

NEW YORK, July 18 - Obesity drugmaker Vivus Inc has delayed its board election, which was scheduled for Thursday morning, as it negotiates with shareholder First Manhattan Co, according to two sources familiar with the situation.

18 Jul 2013

Vivus says FMC rejects offer to settle proxy fight

- Obesity drug maker Vivus Inc, embroiled in a bitter proxy war with its top shareholder First Manhattan Co, said on Wednesday that FMC had rejected an offer to give the sides equal representation on the board.

17 Jul 2013

UPDATE 2-Vivus says FMC rejects offer to settle proxy fight

July 17 - Obesity drug maker Vivus Inc, embroiled in a bitter proxy war with its top shareholder First Manhattan Co, said on Wednesday that FMC had rejected an offer to give the sides equal representation on the board.

17 Jul 2013

Earnings vs. Estimates

Analyst Research Reports

Report Title Price
Provider: Thomson Reuters Stock Report
$25.00
Provider: ValuEngine, Inc.
$25.00
Provider: Pechala's Reports
$25.00
Provider: S&P Capital IQ Quantitative Report
$69.00
Provider: Pechala's Reports
$15.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Search Stocks